论文部分内容阅读
作者等对接受放疗的216例Ⅲ期宫颈鳞癌和59例宫颈腺癌患者之肿瘤组织内免疫细胞浸润与放疗预后进行研究,其中宫颈腺癌Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期(FIGO,WHO诊断标准)分别有8例、15例、25例和11例.放疗选择采用腔内放疗与体外照射相结合的传统方法.~(60)Co(74～148GBq)作腔内放疗源,每周一次,每次A点照射总剂量20～25Gy,4～5次追加体外照射,即以10MeV光子束或~(60)Coγ射线照射前(面积15×15cm)及后(16×18cm)盆区.放疗总剂量50～55Gy.取放疗后的宫颈癌组织,做成4μm厚的石蜡包埋切片HE染色,进行病理核实,以抗牛S-100蛋白抗体、MT_1抗体、L_(26)抗体、LN_3
The authors studied the immune cell infiltration and radiotherapy prognosis in 216 cases of stage Ⅲ cervical squamous cell carcinoma and 59 cases of cervical adenocarcinoma receiving radiotherapy. The cervical adenocarcinoma stage Ⅰ, Ⅱ, Ⅲ and Ⅳ (FIGO , WHO diagnostic criteria) were 8 cases, 15 cases, 25 cases and 11 cases.The radiotherapy choose to use the combination of endotherapy and external beam irradiation in the traditional method. ~ (60) Co (74 ~ 148GBq) for intracavitary radiotherapy source, Once a week, the total dose of 20 ~ 25Gy and the additional dose of 20 ~ 25Gy at the point A were added 4 ~ 5 times before irradiation (area 15 × 15cm) and after (16 × 18cm) with 10MeV photon beam or ~ The total dose of radiotherapy was 50-55 Gy.After radiotherapy, the cervical cancer tissues were taken and stained with 4 μm thick paraffin embedded sections for HE staining and pathological examination. Anti-bovine S-100 protein antibody, MT_1 antibody, L_ (26) Antibody, LN_3